News | Artificial Intelligence | June 13, 2019

Company to showcase its newest artificial intelligence software solution at the SIFEM Medical Conference in France

iCAD Introduces ProFound AI for 2D Mammography in Europe

June 13, 2019 — iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence (AI) platform and follows the launch of ProFound AI for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and U.S. Food and Drug Administration (FDA)-cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference June 13-15, 2019, in Lille, France.

ProFound AI is available for both mammography and tomosynthesis modalities; it is a high-performance, deep-learning, breast cancer detection and workflow solution that offers benefits to radiologists and patients alike. ProFound AI for DBT is clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash reading time for radiologists by 52.7 percent and up to 57.4 percent for dense breast 3-D image analysis.1

“The arrival of the ProFound AI platform has completely changed the way we read tomosynthesis cases. It is a very powerful and extremely useful tool that improves our diagnostic confidence; especially for subtle lesions and dense breasts,” according to Patrick Toubiana, M.D., radiologist, president and cofounder at the C.S.E. Centre Imagerie Médicale Numérique in Paris. “In addition, ProFound AI allows us to optimize our workflow for better reading comfort and a reduction of the interpretation time of the tomosynthesis slices. Today, ProFound AI is a real asset in our daily practice that we could not do without.”

ProFound AI for 2D Mammography and ProFound AI for DBT were designed to rapidly and accurately analyze each image. They provide radiologists with key information, such as certainty of finding lesion and case scores, which assists in clinical decision-making and prioritizing caseloads. Featuring the latest in deep learning AI, the platform also allows for continuously improved performance via ongoing updates.

ProFound AI for 2D Mammography is pending CE Mark in the EU.

For more information: www.icadmed.com

Related Content

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

VIDEO: How iCad Uses AI to Speed Breast Tomosynthesis

 

Reference

Hoffmeister J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed June 4, 2019 via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf


Related Content

News | Artificial Intelligence

March 22, 2023 — Nuance Communications, Inc., a Microsoft company, has announced DAX Express, its next milestone in its ...

Time March 22, 2023
arrow
News | Artificial Intelligence

March 17, 2023 — A new paper published in the Journal of Medical Internet Research describes how generative models such ...

Time March 17, 2023
arrow
News | Radiology Imaging

March 15, 2023 — Regions of the U.S. with an extreme level of socioeconomic disadvantage were less likely to have access ...

Time March 15, 2023
arrow
News | Breast Imaging

March 15, 2023 — In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer ...

Time March 15, 2023
arrow
News | Mammography

March 14, 2023 — Volpara Health Technologies, a global leader in software for the early detection of breast cancer ...

Time March 14, 2023
arrow
Feature | HIMSS | By Melinda Taschetta-Millane

The theme of The Healthcare Information and Management Systems Society (HIMSS23) is Health That Connects + Tech That ...

Time March 14, 2023
arrow
News | Coronavirus (COVID-19)

March 13, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR) ...

Time March 13, 2023
arrow
News | Artificial Intelligence

March 10, 2023 — Breast cancer undisputedly has the highest incidence rate in female patients. Moreover, out of the six ...

Time March 10, 2023
arrow
News | Coronavirus (COVID-19)

March 10, 2023 — Researchers found evidence of heart muscle inflammation in a small number of patients with acute ...

Time March 10, 2023
arrow
Feature | Radiology Business | By Christine Book

With an increasing focus on personalizing the patient experience and enhancing communication between radiologists and ...

Time March 10, 2023
arrow
Subscribe Now